Aardvark Therapeutics, Inc.
AARD
$8.49
-$0.50-5.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.83M | 7.17M | 5.42M | 4.73M | 4.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.86M | 31.08M | 22.79M | 15.57M | 12.20M |
| Operating Income | -40.86M | -31.08M | -22.79M | -15.57M | -12.20M |
| Income Before Tax | -36.64M | -27.72M | -20.59M | -13.85M | -11.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.64 | -27.72 | -20.59 | -13.85 | -11.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.64M | -27.72M | -20.59M | -13.85M | -11.78M |
| EBIT | -40.86M | -31.08M | -22.79M | -15.57M | -12.20M |
| EBITDA | -40.83M | -31.07M | -22.77M | -13.33M | -8.24M |
| EPS Basic | -4.58 | -5.29 | -5.13 | -3.49 | -2.97 |
| Normalized Basic EPS | -2.84 | -3.29 | -3.17 | -2.16 | -1.77 |
| EPS Diluted | -4.58 | -5.29 | -5.13 | -3.49 | -2.97 |
| Normalized Diluted EPS | -2.84 | -3.29 | -3.17 | -2.16 | -1.77 |
| Average Basic Shares Outstanding | 42.94M | 25.21M | 15.99M | 15.89M | 15.86M |
| Average Diluted Shares Outstanding | 42.94M | 25.21M | 15.99M | 15.89M | 15.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |